Literature DB >> 25910293

Relation between serum quantitative HBsAg, ALT and HBV DNA levels in HBeAg negative chronic HBV infection.

Özgür Günal1, Şener Barut, İlker Etikan, Fazilet Duygu, Umut Tuncel, Mustafa Sünbül.   

Abstract

BACKGROUND/AIMS: In this study, we aimed to investigate whether quantitative HBsAg and alanine aminotransferase (ALT) levels correlated with Hepatitis B Virus (HBV) DNA levels in patients with HBeAg negative chronic HBV infection.
MATERIALS AND METHODS: Ninetynine patients were divided into two groups; inactive HBsAg carriers (IC) and active carriers (AC) with HBV DNA>2000 IU/mL. These two groups were compared in terms of ALT and HBsAg levels. Quantitative HBsAg measurements were performed with Elecsys HBsAg II Quant assay (Roche Diagnostic).
RESULTS: Mean age of patients was 43.11±14.79 years. HBsAg and ALT values of IC and AC patients were 2.47±1.35 log10 IU/mL, 3.59±0.97 log10 IU/mL (p=0.0001), and 25.94±13.06 IU/mL, 55.54±82.38 IU/mL (p=0.015), respectively and the difference was significant. When ROC analysis was performed to determine the most appropriate quantitative HBsAg value to define inactive carrier patients, the area under the ROC curve for HBsAg was 0.738 (95% CI:0.637-0.840). A cut-off of 2147 IU/mL revealed sensitivity of 76% and specificity of 70% for diagnosing the IC. Also, a significant correlation was also found between levels of HBV DNA (log) and HBsAg (log) (r: 0.503, p=0.0001).
CONCLUSION: It has been concluded that quantitative measurements of HBsAg could be used to differentiate between IC and AC patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25910293     DOI: 10.5152/tjg.2014.5711

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  2 in total

1.  Role of quantitative hepatitis B surface antigen levels in predicting liver biopsy time in treatment-naive chronic hepatitis B patients.

Authors:  Bengü Tatar; Ayse Acar; Pelın Adar; Sukran Kose
Journal:  Clin Exp Hepatol       Date:  2020-02-17

Review 2.  Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management.

Authors:  Alicia Vachon; Carla Osiowy
Journal:  Viruses       Date:  2021-05-21       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.